The LinkedIn “safety” wrapper is obscuring a very simple direct address:
ICER Scientific Advice: https://isa.icer.org/
ICER formally launched this consulting/scientific-advice service in March 2026. It is aimed at life-science companies and advises on clinical-trial design and evidence-generation strategy, especially evidence likely to matter in later HTA/value assessment. ICER explicitly says the consulting work is kept separate from its independent assessment process.
If that subdomain still refuses to load for you, the ICER announcement describing the service is here: ICER Scientific Advice announcement
https://icer.org/news-insights/press-releases/icer-scientific-advice-offering-2026/?utm_source=chatgpt.com
Institute for Clinical and Economic Review Launches Program to Accelerate the Consideration of Value into Drug Development Programs
– ICER will leverage its health technology assessment (HTA) expertise to encourage better evidence development in clinical trial programs –
BOSTON, March 25, 2026 – The Institute for Clinical and Economic Review (ICER) today formally launched ICER’s Scientific Advice, a new offering to advise companies on evidence generation strategies that will support a more comprehensive assessment of clinical effectiveness and value.
“Today, ICER joins its HTA colleagues across the world who have for years provided scientific advice on clinical trials. ICER’s Scientific Advice will address a key concern that current clinical trials fail to capture the elements of value that matter to key stakeholders. Identifying the right kind of evidence needed from clinical trial programs will ensure that value assessments are a foresight, not an afterthought,” said ICER President and CEO Sarah K. Emond. “Our goal is to improve the evidence that is developed by companies during clinical development to ensure value assessors have the information they need to do a fair assessment at the time of FDA approval.”
Drawing on ICER’s experience having conducted over 100 value assessments geared towards clinicians, payers, and patients, the program will advise on trial designs that successfully capture:
- Clinically meaningful, patient-centered outcomes
- Appropriate surrogate outcomes that predict clinical outcomes
- Data collection outside of the trial environment
- Data that can help inform payer decisions
Based on potential trial results and analogous conditions, ICER will show potential evidence ratings and realistic price ranges, giving a clear view of what different outcomes could mean for a future commercial strategy. One of ICER Scientific Advice’s key goals is to help companies prioritize their clinical assets so the therapies that ultimately receive FDA approval are those with the greatest potential to meaningfully improve patients’ lives. ICER will also help provide consideration of what outcomes patients prioritize through structured focus groups and advise on recruiting diverse patient populations.
ICER Scientific Advice is a completely separate workstream from ICER’s independent and publicly available evidence assessments. Working with ISA does not impact the likelihood that ICER will conduct a health technology assessment of a company’s product in the future, nor will it impact the independence of our assessment should it be selected through our topic selection process.
For more information on the program and its offerings, visit isa.icer.org.
